Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours

NCT03691064 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT03691064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03691064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours
Lead sponsor
Advanced Accelerator Applications
Phase
Observational
Overall status
Active, not recruiting
Start date
November 28, 2018
Completion date
September 30, 2027
Enrollment
1,014 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors